Valparaiso, INNCT07874815Now EnrollingIRB Ready

Pulmonary Disease, Chronic Obstructive Clinical Trial in Valparaiso, IN

Access cutting-edge pulmonary disease, chronic obstructive treatment through this phase 3 clinical trial at a research site in Valparaiso. Study-provided care at no cost to qualified participants.

Sponsored by Merck Sharp & Dohme LLC

Quick Self-Assessment

See if you qualify for this Valparaiso location

Preparing your pre-screening questions…

Expert Care in Valparaiso

Access pulmonary disease, chronic obstructive specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related pulmonary disease, chronic obstructive treatment provided free

Apply for This Valparaiso Location

Check if you qualify for this pulmonary disease, chronic obstructive clinical trial in Valparaiso, IN

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Valparaiso

    Convenient for IN residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Valparaiso site if eligible
  4. 4Begin participation

About This Pulmonary Disease, Chronic Obstructive Study in Valparaiso

The purpose of this study is to evaluate the efficacy and safety of ensifentrine (MK-5884) compared with placebo for the prevention of moderate and severe COPD exacerbation in adults with COPD and a history of exacerbations while receiving SOC treatment. The study will also evaluate the efficacy of ensifentrine compared with placebo in improving lung function, improving health related quality of life, and preventing severe exacerbations.

Sponsor: Merck Sharp & Dohme LLC

Who Can Participate

Inclusion Criteria

Has a diagnosis of Chronic Obstructive Pulmonary Disease (COPD) that was made ≥12 months prior to randomization
Has been on the stable treatment with the same standard of care (SOC) with long-acting muscarinic antagonist (LAMA)/long-acting beta-2 agonist (LABA)/inhaled corticosteroid (ICS) or LAMA/LABA (if ICS is not appropriate), for at least 2 months prior to Screening
Has a documented history of ≥1 moderate or severe COPD exacerbation while on standard of care (SOC) within 1 year of Screening
Is a current or former cigarette smoker with a history of cigarette smoking ≥10 packyears at Screening (number of pack-years = \[number of cigarettes per day/20\] × number of years smoked \[e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per day for 20 years\]). Pipe, cigar, and/or e-cigarette/vape use cannot be used to calculate pack-year history.
Has post-bronchodilator forced expiratory volume 1 (FEV1) ≥25% and \<70% of Predicted Normal Value

Exclusion Criteria

Has a history of intubation for respiratory failure within 1 year of Screening
Is receiving long-term oxygen therapy defined as \>15 hours per day
Uses chronic bilevel positive airway pressure for treatment of respiratory condition unless for treatment of sleep apnea at a stable pressure for at least 3 months
Is currently using or has used a biologic therapy (e.g., dupilumab, mepolizumab, or tozorakimab) within 6 months prior to Screening Visit
Has history of or current malignancy of any organ system, treated or untreated within the past 5 years, except for localized basal or squamous cell carcinoma of the skin.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Valparaiso?

Yes, this clinical trial (NCT07874815) has an active research site in Valparaiso, IN that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Pulmonary Disease, Chronic Obstructive Treatment Options in Valparaiso, IN

If you're searching for pulmonary disease, chronic obstructive treatment options in Valparaiso, IN, this clinical trial (NCT07874815) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Valparaiso research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced pulmonary disease, chronic obstructive specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all pulmonary disease, chronic obstructive clinical trials near you to find additional studies recruiting in your area.

More Ulcerative Colitis Trials in Valparaiso, IN

See all ulcerative colitis clinical trials recruiting in Valparaiso — not just this study.

Browse Ulcerative Colitis Trials in Valparaiso →

Browse More Trials by Condition

Ulcerative Colitis TrialsAnkylosing Spondylitis TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Valparaiso?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Valparaiso, IN